Literature DB >> 26890559

Neurocognitive, Social-Behavioral, and Adaptive Functioning in Preschool Children with Mild to Moderate Kidney Disease.

Stephen R Hooper1, Arlene C Gerson, Rebecca J Johnson, Susan R Mendley, Shlomo Shinnar, Marc B Lande, Matthew B Matheson, Debbie S Gipson, Bruce Morgenstern, Bradley A Warady, Susan L Furth.   

Abstract

OBJECTIVE: The negative impact of end-stage kidney disease on cognitive function in children is well established, but no studies have examined the neurocognitive, social-behavioral, and adaptive behavior skills of preschool children with mild to moderate chronic kidney disease (CKD).
METHOD: Participants included 124 preschool children with mild to moderate CKD, aged 12 to 68 months (median = 3.7 years), and an associated mean glomerular filtration rate (GFR) of 50.0 mL·min·1.73 m. In addition to level of function and percent of participants scoring ≥1 SD below the test mean, regression models examined the associations between biomarkers of CKD (GFR, anemia, hypertension, seizures, and abnormal birth history), and developmental level/IQ, attention regulation, and parent ratings of executive functions, social-behavior, and adaptive behaviors.
RESULTS: Median scores for all measures were in the average range; however, 27% were deemed at risk for a developmental level/IQ <85, 20% were at-risk for attention variability, and parent ratings indicated 30% and 37% to be at risk for executive dysfunction and adaptive behavior problems, respectively. Approximately 43% were deemed at risk on 2 or more measures. None of the disease-related variables were significantly associated with these outcomes, although the presence of hypertension approached significance for attention variability (p < .09). Abnormal birth history and lower maternal education were significantly related to lower developmental level/IQ; seizures were related to lower parental ratings of executive function and adaptive behavior; and abnormal birth history was significantly related to lower ratings of adaptive behavior. When predicting risk status, the logistic regression did evidence both higher GFR and the lack of anemia to be associated with more intact developmental level/IQ.
CONCLUSION: These findings suggest relatively intact functioning for preschool children with mild to moderate CKD, but the need for ongoing developmental surveillance in this population remains warranted, particularly for those with abnormal birth histories, seizures, and heightened disease severity.

Entities:  

Mesh:

Year:  2016        PMID: 26890559      PMCID: PMC4818179          DOI: 10.1097/DBP.0000000000000267

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  23 in total

1.  Neurodevelopment of infants with end-stage renal disease: is it improving?

Authors:  Bradley A Warady
Journal:  Pediatr Transplant       Date:  2002-02

2.  Disturbances of brain maturation and neurodevelopment during chronic renal failure in infancy.

Authors:  G H Bock; C K Conners; J Ruley; C A Samango-Sprouse; J A Conry; I Weiss; G Eng; E L Johnson; C T David
Journal:  J Pediatr       Date:  1989-02       Impact factor: 4.406

3.  Outcome and growth of infants with severe chronic renal failure.

Authors:  J A Kari; C Gonzalez; S E Ledermann; V Shaw; L Rees
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

4.  Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children.

Authors:  G J Schwartz; S Furth; S R Cole; B Warady; A Muñoz
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

5.  Progressive encephalopathy in children with chronic renal insufficiency in infancy.

Authors:  A Rotundo; T E Nevins; M Lipton; L A Lockman; S M Mauer; A F Michael
Journal:  Kidney Int       Date:  1982-03       Impact factor: 10.612

Review 6.  Neurologic development of children with severe chronic renal failure from infancy.

Authors:  M S Polinsky; B A Kaiser; J B Stover; M Frankenfield; H J Baluarte
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

7.  Encephalopathy in young children with moderate chronic renal failure.

Authors:  J F Bale; R L Siegler; P F Bray
Journal:  Am J Dis Child       Date:  1980-06

8.  Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy.

Authors:  David Masur; Shlomo Shinnar; Avital Cnaan; Ruth C Shinnar; Peggy Clark; Jichuan Wang; Erica F Weiss; Deborah G Hirtz; Tracy A Glauser
Journal:  Neurology       Date:  2013-10-02       Impact factor: 9.910

9.  Neurologic-developmental sequelae of chronic renal failure in infancy.

Authors:  M E McGraw; K Haka-Ikse
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

Review 10.  The nervous system and chronic kidney disease in children.

Authors:  Debbie S Gipson; Crista E Wetherington; Peter J Duquette; Stephen R Hooper
Journal:  Pediatr Nephrol       Date:  2004-06-18       Impact factor: 3.714

View more
  16 in total

1.  Environmental lead exposure is associated with neurocognitive dysfunction in children with chronic kidney disease.

Authors:  Rebecca L Ruebner; Stephen R Hooper; Carisa Parrish; Susan L Furth; Jeffrey J Fadrowski
Journal:  Pediatr Nephrol       Date:  2019-07-20       Impact factor: 3.714

Review 2.  Cognitive remediation in pediatric chronic kidney disease and end-stage kidney disease: rationale, candidate interventions, and applicability.

Authors:  Karina Javalkar; Maria E Ferris; Jessica Cuttance; Stephen R Hooper
Journal:  Pediatr Nephrol       Date:  2017-02-25       Impact factor: 3.714

3.  A longitudinal analysis of the effect of anemia on executive functions in children with mild to moderate chronic kidney disease.

Authors:  Nisha S Singh; Rebecca J Johnson; Matthew B Matheson; Joann Carlson; Stephen R Hooper; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2022-07-21       Impact factor: 3.651

Review 4.  Neurocognition in Pediatric Chronic Kidney Disease: A Review of Data From the Chronic Kidney Disease in Children (CKiD) Study.

Authors:  Rebecca J Johnson; Lyndsay A Harshman
Journal:  Semin Nephrol       Date:  2021-09       Impact factor: 4.472

Review 5.  Functional Magnetic Resonance Imaging Findings in Children and Adolescents With Chronic Kidney Disease: Preliminary Findings.

Authors:  Waverly Harrell; Debbie S Gipson; Aysenil Belger; Mina Matsuda-Abedini; Bruce Bjornson; Stephen R Hooper
Journal:  Semin Nephrol       Date:  2021-09       Impact factor: 4.472

6.  Leveraging neuroimaging to understand the impact of chronic kidney disease on the brain.

Authors:  Ellen van der Plas; Lyndsay Harshman
Journal:  Pediatr Nephrol       Date:  2021-11-03       Impact factor: 3.651

7.  Chronic Kidney Disease: Treatment of Comorbidities I: (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease).

Authors:  Amy J Kogon; Lyndsay A Harshman
Journal:  Curr Treat Options Pediatr       Date:  2019-04-15

Review 8.  HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.

Authors:  Dalvir Kular; Iain C Macdougall
Journal:  Pediatr Nephrol       Date:  2018-03-22       Impact factor: 3.714

Review 9.  Mechanisms of cognitive dysfunction in CKD.

Authors:  Davide Viggiano; Carsten A Wagner; Gianvito Martino; Maiken Nedergaard; Carmine Zoccali; Robert Unwin; Giovambattista Capasso
Journal:  Nat Rev Nephrol       Date:  2020-03-31       Impact factor: 28.314

10.  Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease.

Authors:  Allison Tong; Susan Samuel; Michael Zappitelli; Allison Dart; Susan Furth; Allison Eddy; Jaap Groothoff; Nicholas J A Webb; Hui-Kim Yap; Detlef Bockenhauer; Aditi Sinha; Stephen I Alexander; Stuart L Goldstein; Debbie S Gipson; Camilla S Hanson; Nicole Evangelidis; Sally Crowe; Tess Harris; Brenda R Hemmelgarn; Braden Manns; John Gill; Peter Tugwell; Wim Van Biesen; David C Wheeler; Wolfgang C Winkelmayer; Jonathan C Craig
Journal:  Trials       Date:  2016-08-12       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.